Artificial intelligence is dramatically speeding up drug development — and a proprietary survey shows how it’s priming a bigger automation push that’s changing the trajectory of early stage pharma research. The TD Cowen survey of 80 biopharma leaders and insiders finds AI is compressing drug developers’ preclinical costs and timelines by as much as 70%. That’s fueling demand for cutting-edge software, sequencing tools and computer models that will help churn out more experimental treatments in the next five years.
Read the full article: How AI Is Supercharging Drug Development //
Source: https://www.axios.com/2026/07/20/artificial-intelligence-drug-development-impact